News from CTI A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 07, 2016, 01:30 ET Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting

 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced long-term safety and efficacy results from the pivotal Phase 3...


May 19, 2016, 01:30 ET CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting

CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, including additional safety and long-term follow...


May 10, 2016, 16:01 ET CTI BioPharma Reports First Quarter 2016 Financial Results

CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the first quarter ended March 31, 2016. "We continue to believe in...


Apr 21, 2016, 10:00 ET New White Paper Simplifies Physician Engagement and Leadership

 Healthcare industry pundits and executives agree that clinical transformation will not happen unless physicians are actively engaged and...


Apr 20, 2016, 01:30 ET Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment

CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced findings from an investigator-sponsored preclinical study indicating that...


Apr 13, 2016, 01:30 ET CTI BioPharma Announces Presentations at the American Association of Cancer Research Annual Meeting

 CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, pixantrone and tosedostat will be presented...


Feb 16, 2016, 16:01 ET CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results

CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2015. "While we...


Feb 09, 2016, 20:30 ET CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S.

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today provided an update regarding the clinical studies being conducted under the...


Feb 08, 2016, 01:30 ET CTI BioPharma Provides Update On Investigational Agent Pacritinib

 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that the Company received written communication from the U.S. Food...


Jan 13, 2016, 16:30 ET CTI BioPharma Appoints Matthew Perry To Board Of Directors

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Matthew Perry, President of BVF Partners L.P. (BVF Partners) and...


Jan 11, 2016, 01:30 ET CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016

 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress of its lead clinical program in addition to...


Jan 05, 2016, 01:30 ET CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet Medical Need In Myelofibrosis

 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced the completion of...


Dec 14, 2015, 01:30 ET CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has received a $10 million milestone payment from Teva...


Dec 06, 2015, 16:30 ET Analysis Of Phase 2 Tosedostat In Combination With Low Dose Cytarabine Shows High Rates Of Response In Elderly Patients With AML

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an update on results from an investigator-sponsored Phase 2 trial of...


Dec 05, 2015, 09:30 ET Analysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced results from a new...


Dec 04, 2015, 11:15 ET CTI BioPharma Prices Underwritten Public Offering of $55 Million of Convertible Preferred Stock

 CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 55,000 shares of its...


Dec 03, 2015, 16:31 ET CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock

 CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions,...


Nov 24, 2015, 01:30 ET CTI BioPharma Announces United Kingdom National Cancer Research Institute AML Cooperative Group Advances Tosedostat to Next Stage of "Pick-a-Winner" LI-1 Trial for Older Patients with AML or High-Risk MDS

CTI BioPharma Corp. (CTI BioPharma or the Company) (NASDAQ and MTA: CTIC) today announced that the United Kingdom's National Cancer Research...


Nov 24, 2015, 01:00 ET CTI BioPharma to Present at 27th Annual Piper Jaffray Healthcare Conference

 CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the 27th Annual Piper Jaffray Healthcare Conference...


Nov 23, 2015, 01:30 ET CTI BioPharma Initiates Rolling Submission of U.S. New Drug Application for Pacritinib for the Treatment of Patients with Myelofibrosis

 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced the initiation of its rolling new drug application (NDA) to the U.S. Food...


Nov 23, 2015, 01:00 ET CTI BioPharma Announces Presentation of Preclinical Data Demonstrating Potential Synergistic Combination of Pacritinib and an EGFR Inhibitor in Targeting Brain Tumor Initiating Cells

 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced findings from an investigator-sponsored preclinical study showing...


Nov 06, 2015, 01:30 ET CTI BioPharma Announces Data Presentations at the 57th American Society of Hematology Annual Meeting

CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that data highlighting two compounds (pacritinib and tosedostat) from the...


Nov 05, 2015, 16:01 ET CTI BioPharma Reports Third Quarter 2015 Financial Results

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the third quarter ended September 30, 2015. "We are focused on...


Oct 29, 2015, 02:30 ET CTI BioPharma to Report Third Quarter 2015 Financial Results on November 5, 2015

 CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its third quarter 2015 financial results on Thursday,...


Oct 27, 2015, 09:10 ET CTI BioPharma Prices Underwritten Public Offering of $50 Million of Convertible Preferred Stock

CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 50,000 shares of its Series...